2.75k followers • 19 symbols +0.08% Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has experienced volatility amid the release of another spate of earnings reports. Even as the earnings season winds down, the upcoming week ...
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of -16.67% and -13.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Henderson, Nevada-based company said it had profit of 13 cents. Losses, adjusted for one-time gains and costs, came to 21 cents per share. The biotechnology company posted revenue ...
In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.
In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.
In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.